Nabumetone is an anti-inflammatory drug (NSAID) for the treatment of pain and inflammation associated with rheumatoid arthritis and osteoarthritis. The incidence of gastrointestinal ulcers associated with nabumetone appears to be lower than for other NSAIDs, suggesting that the drug May be a preferential inhibitor of cyclooxygenase-2. Because the drug exhibits poor aqueous solubility, the researchers tried to improve the solubility by using various techniques. Efforts are also made to encourage the rapid development of therapeutic efficacy of the formulation of an effervescent and chewable tablet annular tablet with molded triturate tablet.
Although widely accepted conventional solid oral dosage forms, pediatric, geriatric, and bedridden patients have difficulty swallowing. In addition, for poorly soluble drugs, dissolution of the drug from the tablet is the rate-limiting step in the process of drug absorption. Because the rate and extent of drug absorption is determined by the pace and extent of dissolution of tablets of drugs, drugs with low aqueous solubility because of the irregularity or incomplete absorption from the gastrointestinal tract intestinal intestinal tract are known to pose potential bioavailability.
Because Nabumetone is practically insoluble in water, absorption will depend on the speed of dissolution. This study attempts to solve this problem by formulating a complex with the drug before?-Cyclodextrin (?-CD) as quickly disperse porous tablet. These tablets are designed to disappear quickly and completely to facilitate complete dissolution of drug absorption after oral administration. Inclusion complexes were successfully used to improve solubility, dissolution and bioavailability of poorly soluble drugs.
Friday, May 29, 2009
Subscribe to:
Posts (Atom)